Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

PET/CT in therapy evaluation of patients with lung cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Drug transporters in breast cancer: response to anthracyclines and taxanes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Immunosuppression and risk of cervical cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Human papillomavirus testing and genotyping in cervical screening

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Stomach interference in 82Rb-PET myocardial perfusion imaging

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.

Original languageEnglish
JournalExpert Review of Anticancer Therapy
Volume14
Issue number5
Pages (from-to)595-620
Number of pages26
ISSN1473-7140
DOIs
Publication statusPublished - May 2014

    Research areas

  • Humans, Lung Neoplasms, Multimodal Imaging, Positron-Emission Tomography, Tomography, X-Ray Computed

ID: 45026268